Celeris Therapeutics

High-Level Overview

Celeris Therapeutics is an AI-first biotechnology company developing novel degrader drugs, known as proximity-inducing compounds (PICs) or protein degraders, to target undruggable pathogenic proteins linked to diseases like Parkinson's, Alzheimer's, and various cancers.[1][2][4] It serves pharmaceutical and biotech partners through collaborations while advancing an in-house pipeline, using its Celeris One™ platform—powered by machine learning and geometric deep learning—to accelerate design of E3 ligase-based degraders, linker optimization, and compound synthesis, supported by automated wet labs.[1][2][3] The company solves the challenge of "undruggable" targets by predicting biomolecular interactions and generating new chemical entities faster than traditional methods, addressing high unmet needs in oncology and CNS disorders with global operations in Menlo Park (CA), London (UK), and Graz (Austria).[1][2][4]

Founded in 2020-2021, Celeris has gained early traction via seed funding (including from EIF-backed i&i Biotech Fund), big pharma partnerships, and team expansion to ~25 new R&D roles, positioning it for preclinical advancement.[1][3][4]

Origin Story

Celeris Therapeutics emerged from the vision of co-founders Christopher Trummer (CEO, with expertise in biotech and computer science) and Jakob Hohenberger (serial tech entrepreneur entering life sciences).[1][3][4] Hohenberger, driven by the lack of curative treatments for diseases like Parkinson's ("It's 2022, and there's no curative treatment"), researched markets and pivoted to biotech in 2020, partnering with Trummer who brought a concrete AI-driven plan for degrader tech.[4] They started in a dry lab, coding and prototyping, before securing seed funding and establishing wet labs in Graz, Austria.[4][5]

Pivotal moments include closing seed rounds with investors like APEX Ventures and i&i Biotech Fund to fuel R&D, expanding to Silicon Valley, and onboarding experts like Dr. James Harling, a PROTAC pioneer from Arvinas, to lead innovation.[1][3][4] This blend of AI, computational chemistry, and wet-lab validation humanizes their mission: "benefiting people" by tackling incurable diseases.[4]

Core Differentiators

• AI-Powered Celeris One™ Platform: Uses structure-based geometric deep learning for precise E3 ligase prioritization, linker design, and active compound selection; integrates rapid in-house automated labs for experimental feedback loops, enabling faster, more efficient degrader development than conventional approaches.[1][2][3]
• Focus on Undruggable Targets: Designs PICs™ to degrade proteins causing Parkinson's, Alzheimer's, cancers, and more—targets previously inaccessible to small molecules—via active machine learning for biomolecular predictions and novel chemical space exploration.[1][2][4]
• Hybrid Model: Collaborates with pharma/biotech on co-development across therapeutic areas while pursuing proprietary programs; global footprint (US, UK, Austria) combines dry/wet labs for end-to-end execution.[1][2][4]
• Proven Expertise: Leadership from PROTAC veterans and serial founders accelerates clinical translation, as seen in early partnerships and preclinical momentum.[1][4]

Role in the Broader Tech Landscape

Celeris rides the AI-drug discovery wave intersecting with targeted protein degradation (TPD), a trend exploding as degraders like PROTACs (pioneered by alumni like Arvinas) enter clinics, expanding the "druggable" proteome beyond traditional inhibitors.[1][2] Timing is ideal amid post-2020 AI booms (e.g., AlphaFold impacts) and biotech's push for undruggable targets in neurodegeneration and oncology, where ~80% of disease proteins remain untapped.[3][4]

Market forces favor Celeris: surging VC into AI-biotech hybrids, big pharma's degrader deals (e.g., partnerships noted), and regulatory tailwinds for novel modalities.[2][4] It influences the ecosystem by democratizing degrader design—faster synthesis cycles reduce costs/risks—potentially lowering barriers for startups and incumbents tackling CNS/oncology gaps.[1][5]

Quick Take & Future Outlook

Celeris is poised for preclinical milestones and Series A, with big pharma collaborations likely yielding first IND filings in Parkinson's or oncology within 2-3 years, bolstered by wet-lab scaling and AI refinements.[1][2][4] Trends like multimodal AI (integrating wet data loops) and TPD expansion to new E3 ligases will propel it, amid a market projected to grow as degraders prove in trials.[3]

Its influence may evolve from pioneer to platform leader, licensing Celeris One™ widely or spinning out assets, ultimately delivering the first AI-designed degrader cures—echoing its origin as a mission to alleviate "incurable" suffering.[4]